uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of “Hold” by Analysts

uniQure N.V. (NASDAQ:QURE) has been given an average rating of “Hold” by the seventeen brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $41.3333.

Several equities research analysts have recently commented on QURE shares. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $15.00 to $60.00 in a research note on Monday. William Blair reiterated a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Stifel Nicolaus set a $14.00 price target on uniQure in a report on Monday, March 2nd. Wolfe Research initiated coverage on uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, Chardan Capital raised their price objective on uniQure from $16.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Analyst upgrades and price‑target increases lifting sentiment — Wells Fargo upgraded QURE to “overweight” with a $60 PT and Chardan boosted its PT to $31 with a buy rating; RBC moved to “outperform” with a $35 PT. These calls drove constructive re‑ratings and buy-side interest. Wells Fargo Upgrade Chardan PT Raise
• Positive Sentiment: Regulatory leadership change in the FDA (CBER director Vinay Prasad’s announced exit) is being interpreted by the market as easing near‑term regulatory risk for gene‑therapy programs, prompting a sector rally that lifted uniQure shares. Blockonomi: Stock Soars on FDA Exit Benzinga: Biotech Reaction
• Neutral Sentiment: Analyst and media coverage is spotlighting uniQure ahead of key AMT‑130 catalysts; these pieces increase visibility but do not change fundamentals absent clinical or regulatory news. 24/7 Wall St. Analyst Interest
• Negative Sentiment: Multiple law firms have filed or publicized investor notices seeking lead plaintiffs for a securities class action covering Sept. 24–Oct. 31, 2025 (claims tied to AMT‑130 disclosures). The proliferation of filings (Faruqi, Hagens Berman, Levi & Korsinsky, Portnoy, Rosen) creates legal and disclosure risk and could impose costs or settlement pressure. Faruqi & Faruqi Notice Hagens Berman Alert Levi & Korsinsky Notice Portnoy Law Firm Rosen Law Firm Notice
• Negative Sentiment: Coverage highlighting “confusion” and shifting narratives around uniQure’s disputes with the FDA over AMT‑130 suggests ongoing regulatory uncertainty that could weigh on valuation until resolved. The Pharma Letter: Confusion Grows Yahoo Finance: Shifting Narrative

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 14,581 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $132,103.86. Following the completion of the sale, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at approximately $5,985,561.48. This represents a 2.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the sale, the director owned 32,342 shares in the company, valued at approximately $796,260.04. The trade was a 44.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 81,399 shares of company stock worth $1,527,645 in the last ninety days. Corporate insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Several institutional investors and hedge funds have recently modified their holdings of QURE. Avoro Capital Advisors LLC boosted its holdings in uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares during the period. Aberdeen Group plc raised its holdings in uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after acquiring an additional 738,897 shares during the period. State Street Corp raised its holdings in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares during the period. JPMorgan Chase & Co. lifted its position in shares of uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares in the last quarter. Finally, Jefferies Financial Group Inc. purchased a new position in shares of uniQure in the second quarter valued at about $29,217,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $17.99 on Tuesday. The firm has a 50 day moving average of $21.90 and a 200 day moving average of $29.64. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -5.21 and a beta of 0.73. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. On average, research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.